Journal ArticleDOI
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma
Michele Moschetta,Giulia Di Pietro,Roberto Ria,Antonio Gnoni,Giuseppe Mangialardi,Attilio Guarini,Paolo Ditonno,Pellegrino Musto,Fiorella D'Auria,Maria Rosaria Ricciardi,Franco Dammacco,Domenico Ribatti,Angelo Vacca +12 more
Reads0
Chats0
TLDR
Evidence is provided that the exposure of bone marrow macrophages in MM during the treatment with ZOL and BZ, alone and or in combination, impacts their angiogenic and vasculogenic properties, suggesting that these cells may be considered as a target of both drugs in MM patients.About:
This article is published in European Journal of Cancer.The article was published on 2010-01-01. It has received 65 citations till now. The article focuses on the topics: Bone marrow & Bortezomib.read more
Citations
More filters
Journal ArticleDOI
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
TL;DR: Increasing evidence is reviewed to support a disease-modifying effect of bone-targeted treatment and the impact on clinical management that reproductive hormones are an important treatment modifier to take into account.
Journal ArticleDOI
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.
TL;DR: The role of bisphosphonates is expected to further expand in the near future outside the field of osteoporosis and to open up new avenues in the treatment of malignancies.
Journal ArticleDOI
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
Giovanni D'Arena,Paolo G. Gobbi,Chiara Broglia,Stefano Sacchi,Giovanni Quarta,Luca Baldini,Emilio Iannitto,Antonietta Falcone,Roberto Guariglia,Giuseppe Pietrantuono,Oreste Villani,Maria Carmen Martorelli,Giovanna Mansueto,Grazia Sanpaolo,Nicola Cascavilla,Pellegrino Musto +15 more
TL;DR: The administration of pamidronate in asymptomatic myeloma, while reducing bone involvement at progression, did not decrease the risk of transformation and the time to progression into overt Myeloma.
Journal ArticleDOI
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Leonardo Mirandola,Yuefei Yu,Kitty Chui,Marjorie R. Jenkins,Everardo Cobos,Constance M. John,Maurizio Chiriva-Internati +6 more
TL;DR: It is demonstrated that galectin-3C alone was efficacious in a xenograft mouse model of human MM, and that it enhanced the anti-tumor activity of bortezomib in vitro and in vivo.
Journal ArticleDOI
Immunomodulatory effects of anti-angiogenic drugs.
Annkristin Heine,Stefanie Andrea Erika Held,Anita Bringmann,Tobias A. W. Holderried,Peter Brossart +4 more
TL;DR: Recent reports on the immunomodulatory function of lately introduced clinically applied anti-angiogenic compounds, such as the humanized monoclonal antibody against VEGF bevacizumab, the small molecule TKIs sunitinib, sorafenib, imatinib, dasatinIB, nilotinib and the proteasome inhibitor bortezomib are summarized.
References
More filters
Journal ArticleDOI
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Ting-Chao Chou,Paul Talalay +1 more
TL;DR: A generalized method for analyzing the effects of multiple drugs and for determining summation, synergism and antagonism has been proposed and has been used to analyze experimental data obtained from enzymatic, cellular and animal systems.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle,J. Anthony Child,Kenneth C. Anderson,Bart Barlogie,Régis Bataille,William I. Bensinger,Joan Bladé,Mario Boccadoro,William S. Dalton,Meletios A. Dimopoulos,Benjamin Djulbegovic,Mark T. Drayson,Brian G.M. Durie,Thiery Facon,Rafael Fonseca,Gösta Gahrton,Philip R. Greipp,Jean Luc Harousseau,David P. Harrington,Mohamad A. Hussein,Douglas E. Joshua,Heinz Ludwig,Gareth J. Morgan,Martin M. Oken,R. L. Powles,Paul G. Richardson,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Chaim Shustik,Bhawna Sirohi,Pieter Sonneveld,Guido J Tricot,Ingemar Turesson,Brian G Van Ness,David H. Vesole,Donna M. Weber,Jan Westin,Keith Wheatley +38 more
TL;DR: The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data.
Journal Article
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Teru Hideshima,Paul G. Richardson,Dharminder Chauhan,Vito J. Palombella,Peter J. Elliott,Julian Adams,Kenneth C. Anderson +6 more
TL;DR: It is demonstrated that the proteasome inhibitor PS-341 both acts directly on MM cells and alters cellular interactions and cytokine secretion in the BM millieu to inhibit tumor cell growth, induce apoptosis, and overcome drug resistance.